Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.4.3.2 - L-amino-acid oxidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aneurysm, Infected
Convexity Subarachnoid Hemorrhage, Pseudomonas Aeruginosa (PA) Infective Endocarditis and Left Atrial Appendage Occluder (LAAO) Device Infection. A Case Report.
Aortic Valve Stenosis
"One-Stop Shop": Safety of Combining Transcatheter Aortic Valve Replacement and Left Atrial Appendage Occlusion.
Atrial Fibrillation
"One-Stop Shop": Safety of Combining Transcatheter Aortic Valve Replacement and Left Atrial Appendage Occlusion.
Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery.
Causes of death and morbidity in patients with atrial fibrillation after left atrial appendage occlusion.
Comparison of fluoroscopy and transesophageal echocardiogram for intra-procedure device surveillance assessment during implantation of Watchman.
Direct Current Cardioversion of Atrial Fibrillation in Patients With Left Atrial Appendage Occlusion Devices.
Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial.
Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion.
Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation.
Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry.
Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding (from the Amplatzer Cardiac Plug Multicenter Registry).
Left atrial appendage occlusion in recurrent ischaemic stroke, a multicentre experience.
Left atrial appendage occlusion with Amplatzer Cardio Plug is an acceptable therapeutic option for prevention of stroke recurrence in patients with non-valvular atrial fibrillation and contraindication or failure of oral anticoagulation with acenocumarol.
Left Atrial Appendage Occlusion With Left Ventricular Assist Device Decreases Thromboembolic Events.
Left atrial appendage occlusion with the Amplatzer Cardiac Plug could improve survival and prevent thrombo-embolic and major bleeding events in atrial fibrillation patients with increased bleeding risk.
Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study.
Long-term effect of anticoagulation following left atrial appendage occlusion with the LARIAT device in patients with nonvalvular atrial fibrillation: impact on thromboembolism, bleeding and mortality. Real life data.
Nonvalvular atrial fibrillation in high-hemorrhagic-risk patients: state of the art of percutaneous left atrial appendage occlusion.
Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies.
Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registry.
Percutaneous left atrial appendage occlusion.
Peri-procedural silent cerebral infarcts after left atrial appendage occlusion.
Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion.
Pulmonary ridge coverage and device-related thrombosis after left atrial appendage occlusion.
Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study).
Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage.
Safety and feasibility of combined atrial fibrillation ablation and left atrial appendage occlusion after left atrial appendage electrical isolation.
Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry.
Systematic Review of Contiguous Vessel and Valve Injury Associated with Endocardial Left Atrial Appendage Occlusion Devices.
Utilization and procedural adverse outcomes associated with Watchman device implantation.
Why should cardiac surgeons occlude the left atrial appendage percutaneously?
[Left atrial appendage occlusion in elderly].
[Safety and effectiveness of left atrial appendage occlusion in patients with atrial fibrillation and end-stage renal disease undergoing long-term hemodialysis].
Atrial Flutter
Direct Current Cardioversion of Atrial Fibrillation in Patients With Left Atrial Appendage Occlusion Devices.
Utilization and procedural adverse outcomes associated with Watchman device implantation.
Autoimmune Diseases
[The role of IL4I1 in immunoregulation: An update].
Blister
The relationship between clinics and the venom of the causative Amazon pit viper (Bothrops atrox).
Carcinoma, Hepatocellular
BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells.
Cardiac Tamponade
Comparison of Efficacy and Safety of Left Atrial Appendage Occlusion in Patients Aged <75 to ?75 Years.
Delayed presentation of pulmonary artery perforation by an Amulet left atrial appendage closure device.
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: The LAAO Italian Multicenter Registry.
Left atrial appendage closure device complicated by late-onset pericardial effusion and tamponade: a case report.
[New Treatment for Vascular Thrombosis Prevention in Patients With Atrial Fibrillation: Left Atrial Appendage Occlusion].
Cerebral Hemorrhage
Peri-procedural silent cerebral infarcts after left atrial appendage occlusion.
Demyelinating Diseases
IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation.
[The role of IL4I1 in immunoregulation: An update].
Dermatitis Herpetiformis
Presence of L-amino-acid oxidase in the blood in pemphigus, dermatitis herpetiformis Duhring and herpes zoster.
Diabetes Mellitus
Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation.
Embolic Stroke
Left atrial appendage occlusion in patients with atrial fibrillation and large prevalence of prior intracranial bleeding.
Embolism
Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion.
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: The LAAO Italian Multicenter Registry.
Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial.
Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).
[The current state of knowledge on the percutaneous elimination of the left atrial appendage based on data from randomized trials and clinical registries].
Encephalomyelitis
IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation.
Encephalomyelitis, Autoimmune, Experimental
IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation.
Endocarditis
Convexity Subarachnoid Hemorrhage, Pseudomonas Aeruginosa (PA) Infective Endocarditis and Left Atrial Appendage Occluder (LAAO) Device Infection. A Case Report.
Granuloma
Dichotomy between factors inducing the immunosuppressive enzyme IL-4-induced gene 1 (IL4I1) in B lymphocytes and mononuclear phagocytes.
The IL4I1 Enzyme: A New Player in the Immunosuppressive Tumor Microenvironment.
Heart Diseases
Unconventional combination of left atrial appendage device occlusion in patients with atrial fibrillation who needed concomitant catheter interventions for underlying structural heart disease.
Heart Failure
Analysis of outcome of 6-month readmissions after percutaneous left atrial appendage occlusion.
Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion.
Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation.
Percutaneous left atrial appendage occlusion procedures in patients with heart failure.
Heart Failure, Systolic
Percutaneous left atrial appendage occlusion procedures in patients with heart failure.
Heart Septal Defects, Atrial
Unconventional combination of left atrial appendage device occlusion in patients with atrial fibrillation who needed concomitant catheter interventions for underlying structural heart disease.
Herpes Zoster
Presence of L-amino-acid oxidase in the blood in pemphigus, dermatitis herpetiformis Duhring and herpes zoster.
Hypertension
Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation.
Left Atrial Appendage Occlusion With Left Ventricular Assist Device Decreases Thromboembolic Events.
Infections
Barbel steed (Hemibarbus labeo) NK-lysin protects against Aeromonas hydrophila infection via immunomodulatory activity.
Characterization of ayu (Plecoglossus altivelis) urocortin: The function of an endocrine factor in monocyte/macrophage regulation.
Convexity Subarachnoid Hemorrhage, Pseudomonas Aeruginosa (PA) Infective Endocarditis and Left Atrial Appendage Occluder (LAAO) Device Infection. A Case Report.
Identification, expression profile and analysis of the antimicrobial activity of collectin 11 (CL-11, CL-K1), a novel complement-associated pattern recognition molecule, in half-smooth tongue sole (Cynoglossus semilaevis).
IL4I1 Accelerates the Expansion of Effector CD8+ T Cells at the Expense of Memory Precursors by Increasing the Threshold of T-Cell Activation.
l-amino acid oxidase expression profile and biochemical responses of rabbitfish (Siganus oramin) after exposure to a high dose of Cryptocaryon irritans.
Molecular characterization and functional analysis of two distinct liver-expressed antimicrobial peptide 2 (LEAP-2) genes in large yellow croaker (Larimichthys crocea).
Molecular characterization of an IL-1? gene from ayu, Plecoglossus altivelis.
Molecular characterization of purinergic receptor P2X4 involved in Japanese flounder (Paralichthys olivaceus) innate immune response and its interaction with ATP release channel Pannexin1.
Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity.
Molecular characterization, expression analysis and function identification of Pf_TNF-? and its two receptors Pf_TNFR1 and Pf_TNFR2 in yellow catfish (Pelteobagrus fulvidraco).
[The role of IL4I1 in immunoregulation: An update].
Intracranial Hemorrhages
Feasibility of Left Atrial Appendage Closure in Atrial Fibrillation Patients with a History of Intracranial Bleeding: A Systematic Review of Observational Studies.
Ischemic Attack, Transient
Clinical follow-up of left atrial appendage occlusion in patients with atrial fibrillation ineligible of oral anticoagulation treatment-a systematic review and meta-analysis.
Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation.
Left Atrial Appendage Occlusion as Adjunctive Therapy to Anticoagulation for Stroke Recurrence.
Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial.
Percutaneous Left Atrial Appendage Occlusion Yields Favorable Neurological Outcomes in Patients with Non-Valvular Atrial Fibrillation.
Ischemic Stroke
Clinical follow-up of left atrial appendage occlusion in patients with atrial fibrillation ineligible of oral anticoagulation treatment-a systematic review and meta-analysis.
Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation.
Comparative data on left atrial appendage occlusion efficacy and clinical outcomes by age group in the Amplatzer™ Amulet™ Occluder Observational Study.
Left atrial appendage occlusion for ischemic stroke prevention in patients with non-valvular atrial fibrillation: clinical expert opinion and consensus statement for the Asian-Pacific region.
Left atrial appendage occlusion in recurrent ischaemic stroke, a multicentre experience.
Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial.
Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study.
Observed versus Expected Ischemic and Bleeding Events Following Left Atrial Appendage Occlusion.
Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug.
Percutaneous Left Atrial Appendage Occlusion Yields Favorable Neurological Outcomes in Patients with Non-Valvular Atrial Fibrillation.
Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).
The Impact of CHA2DS2-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study.
Kidney Failure, Chronic
Contrast-free, echocardiography-guided left atrial appendage occlusion (LAAo): a propensity-matched comparison with conventional LAAo using the AMPLATZER™ Amulet™ device.
Percutaneous left atrial appendage closure, a safe alternative to anticoagulation for patients with nonvalvular atrial fibrillation and end-stage renal disease on hemodialysis: A single center experience.
[Safety and effectiveness of left atrial appendage occlusion in patients with atrial fibrillation and end-stage renal disease undergoing long-term hemodialysis].
Leukemia, Lymphocytic, Chronic, B-Cell
The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.
Lung Injury
GC-MS based metabolomic profiling of lung tissue couple with network pharmacology revealed the possible protection mechanism of Pudilan Xiaoyan Oral Liquid in LPS-induced lung injury of mice.
Lymphocytic Choriomeningitis
IL4I1 Accelerates the Expansion of Effector CD8+ T Cells at the Expense of Memory Precursors by Increasing the Threshold of T-Cell Activation.
Lymphoma
Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation.
Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.
The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.
Lymphoma, B-Cell
Inhibition of antitumor T-cell response and immune escape in mice associated with Interleukin 4-induced gene 1 expression.
Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.
The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.
Lymphoma, Follicular
The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.
Melanoma
Emerging Role of IL-4-Induced Gene 1 as a Prognostic Biomarker Affecting the Local T-Cell Response in Human Cutaneous Melanoma.
IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.
Inhibition of antitumor T-cell response and immune escape in mice associated with Interleukin 4-induced gene 1 expression.
Interleukin 4-Induced Gene 1 as an Emerging Regulator of B-Cell Biology and its Role in Cutaneous Melanoma.
The IL4I1 Enzyme: A New Player in the Immunosuppressive Tumor Microenvironment.
Mesothelioma
Inhibition of antitumor T-cell response and immune escape in mice associated with Interleukin 4-induced gene 1 expression.
Multiple Sclerosis
IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation.
Myotoxicity
Venomics of the Central American Lyre Snake Trimorphodon quadruplex (Colubridae: Smith, 1941) from Costa Rica.
Neoplasms
A cytotoxin isolated from Agkistrodon acutus snake venom induces apoptosis via Fas pathway in A549 cells.
Alterations of the immunosuppressive IL4I1 enzyme activity induced by naturally occurring SNP/mutations.
An Overview of l-Amino Acid Oxidase Functions from Bacteria to Mammals: Focus on the Immunoregulatory Phenylalanine Oxidase IL4I1.
Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism.
Antiproliferative Activity of King Cobra (Ophiophagus hannah) Venom l-Amino Acid Oxidase.
Biopolymers from marine invertebrates. XI. Characterization of an antineoplastic glycoprotein, dolabellanin A, from the albumen gland of a sea hare, Dolabella auricularia.
BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells.
Cytotoxicity of snake venom enzymatic toxins: phospholipase A2 and l-amino acid oxidase.
Emerging Role of IL-4-Induced Gene 1 as a Prognostic Biomarker Affecting the Local T-Cell Response in Human Cutaneous Melanoma.
IL4-induced gene 1 is secreted at the immune synapse and modulates TCR activation independently of its enzymatic activity.
IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.
IL4I1 Is Expressed by Head-Neck Cancer-Derived Mesenchymal Stromal Cells and Contributes to Suppress T Cell Proliferation.
Inhibition of antitumor T-cell response and immune escape in mice associated with Interleukin 4-induced gene 1 expression.
Interleukin 4-Induced Gene 1 as an Emerging Regulator of B-Cell Biology and its Role in Cutaneous Melanoma.
Isolation and characterization of ACTX-6: a cytotoxic L-amino acid oxidase from Agkistrodon acutus snake venom.
King cobra (Ophiophagus hannah) venom L-amino acid oxidase induces apoptosis in PC-3 cells and suppresses PC-3 solid tumor growth in a tumor xenograft mouse model.
Purification of dolabellanin-C an antineoplastic glycoprotein in the body fluid of a sea hare, Dolabella auricularia.
RNA Sequencing revealed differentially expressed genes functionally associated with immunity and tumor suppression during latent phase infection of a vv?+?MDV in chickens.
The IL4I1 Enzyme: A New Player in the Immunosuppressive Tumor Microenvironment.
The immunosuppressive enzyme IL4I1 promotes FoxP3(+) regulatory T lymphocyte differentiation.
The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.
What role for AHR activation in IL4I1-mediated immunosuppression ?
[The role of IL4I1 in immunoregulation: An update].
Paralysis
IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation.
Pemphigus
Presence of L-amino-acid oxidase in the blood in pemphigus, dermatitis herpetiformis Duhring and herpes zoster.
Pericardial Effusion
Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis.
Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion.
Left atrial appendage closure device complicated by late-onset pericardial effusion and tamponade: a case report.
Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion.
Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry.
Prostatic Neoplasms
King cobra (Ophiophagus hannah) venom L-amino acid oxidase induces apoptosis in PC-3 cells and suppresses PC-3 solid tumor growth in a tumor xenograft mouse model.
Renal Insufficiency, Chronic
Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation.
[Monocentric experience of left atrial appendage occlusion among patients with advanced chronic kidney disease and non-valvular atrial fibrillation].
Stroke
Ablation for Atrial Fibrillation Combined With Left Atrial Appendage Closure.
Ablation of Atrial Fibrillation in Combination with Left Atrial Appendage Occlusion in A Single Procedure. Rationale and Technique.
An updated systematic review and meta-analysis of early outcomes after left atrial appendage occlusion.
Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery.
Causes of death and morbidity in patients with atrial fibrillation after left atrial appendage occlusion.
Cerebral Protection Devices during Transcatheter Interventions: Indications, Benefits, and Limitations.
Characterization of Cerebrovascular Events After Left Atrial Appendage Occlusion.
Clinical follow-up of left atrial appendage occlusion in patients with atrial fibrillation ineligible of oral anticoagulation treatment-a systematic review and meta-analysis.
Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation.
Clinical outcomes of bivalirudin versus heparin in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion.
Combination of catheter ablation for non-valvular atrial fibrillation and left atrial appendage occlusion in a single procedure.
Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.
Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion.
Gender difference in left atrial appendage occlusion outcomes: Results from the Amplatzer™ Amulet™ Observational Study.
Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation.
Impact of the CHA2DS2-VASc score on late clinical outcomes in patients undergoing left atrial appendage occlusion.
Impact of Thrombocytopenia in Patients With Atrial Fibrillation Undergoing Left Atrial Appendage Occlusion: A Propensity-Matched Comparison of 190 Consecutive Watchman Implantations.
In silico Optimization of Left Atrial Appendage Occluder Implantation Using Interactive and Modeling Tools.
Incidence and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: Insights from the Amplatzer™ Amulet™ LAA Occluder Observational Study.
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: The LAAO Italian Multicenter Registry.
LAAO during cardiac surgery prevents stroke.
Left atrial appendage closure using AMPLATZER™ devices: A large, multicenter, Italian registry.
Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey.
Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey.
Left Atrial Appendage Occlusion as Adjunctive Therapy to Anticoagulation for Stroke Recurrence.
Left atrial appendage occlusion for ischemic stroke prevention in patients with non-valvular atrial fibrillation: clinical expert opinion and consensus statement for the Asian-Pacific region.
Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis.
Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry.
Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: results of the European Heart Rhythm Association survey.
Left Atrial Appendage Occlusion in High Bleeding Risk Patients.
Left atrial appendage occlusion in recurrent ischaemic stroke, a multicentre experience.
Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial.
Left atrial appendage occlusion with Amplatzer Cardio Plug is an acceptable therapeutic option for prevention of stroke recurrence in patients with non-valvular atrial fibrillation and contraindication or failure of oral anticoagulation with acenocumarol.
Left atrial appendage occlusion with lambre in atrial fibrillation: Initial European experience.
Left Atrial Appendage Occlusion With Left Ventricular Assist Device Decreases Thromboembolic Events.
Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study.
Left Atrial Appendage Occlusion: A Narrative Review.
Long-term effect of anticoagulation following left atrial appendage occlusion with the LARIAT device in patients with nonvalvular atrial fibrillation: impact on thromboembolism, bleeding and mortality. Real life data.
Long-term outcomes and periprocedural safety and efficacy of percutaneous left atrial appendage closure in a United Kingdom tertiary center: An 11-year experience.
Non-vitamin K antagonist oral anticoagulation versus left atrial appendage occlusion for primary and secondary stroke prevention after cardioembolic stroke.
Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies.
Percutaneous Left Atrial Appendage Closure with WATCHMAN™ device: peri-procedural and mid-term outcomes from the TRAPS Registry.
Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review.
Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug.
Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registry.
Percutaneous Left Atrial Appendage Occlusion Yields Favorable Neurological Outcomes in Patients with Non-Valvular Atrial Fibrillation.
Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding.
Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion.
Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).
Reduction in risk of stroke and bleeding after left atrial appendage closure with LARIAT device in patients with increased risk of stroke and bleeding: Long term results.
Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage.
Role of Endovascular Closure of the Left Atrial Appendage in Stroke Prevention for Atrial Fibrillation.
Short-Term Antiplatelet Versus Anticoagulant Therapy After Left Atrial Appendage Occlusion: A Systematic Review and Meta-Analysis.
Stroke Risk in Patients With Atrial Fibrillation Undergoing Electrical Isolation of the Left Atrial Appendage.
Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis.
Thromboembolic events and need for anticoagulation therapy following left atrial appendage occlusion in patients with electrical isolation of the appendage.
Thrombus Formation After Left Atrial Appendage Occlusion With the Amplatzer Amulet Device.
Transcatheter Aortic Valve Replacement and Left Atrial Appendage Occlusion - A Stitch in Time?
Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy.
Unprotected discharge: absence of stroke prevention strategies in patients with atrial fibrillation admitted for bleeding.
[Clinical analysis of left atrial appendage occlusion for stroke prevention in elderly patients with atrial fibrillation].
[Left atrial appendage occlusion in elderly].
[New Treatment for Vascular Thrombosis Prevention in Patients With Atrial Fibrillation: Left Atrial Appendage Occlusion].
[Oral anticoagulation and platelet inhibition after atrial appendage occlusion].
[The current state of knowledge on the percutaneous elimination of the left atrial appendage based on data from randomized trials and clinical registries].
Thrombocytopenia
Impact of Thrombocytopenia in Patients With Atrial Fibrillation Undergoing Left Atrial Appendage Occlusion: A Propensity-Matched Comparison of 190 Consecutive Watchman Implantations.
Thromboembolism
Antithrombotic strategies after interventional left atrial appendage closure: an update.
Left atrial appendage closure using AMPLATZER™ devices: A large, multicenter, Italian registry.
Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug.
Left Atrial Appendage Occlusion in the Management of Stroke in Patients With Atrial Fibrillation.
Long-term effect of anticoagulation following left atrial appendage occlusion with the LARIAT device in patients with nonvalvular atrial fibrillation: impact on thromboembolism, bleeding and mortality. Real life data.
Percutaneous devices for left atrial appendage occlusion: A contemporary review.
[Safety and effectiveness of left atrial appendage occlusion in patients with atrial fibrillation and end-stage renal disease undergoing long-term hemodialysis].
Thrombosis
Device-Related Thrombus After Left Atrial Appendage Occlusion With the Amulet Device.
Direct Current Cardioversion of Atrial Fibrillation in Patients With Left Atrial Appendage Occlusion Devices.
Feasibility of Left Atrial Appendage Occlusion in Left Atrial Appendage Thrombus: A Systematic Review.
In silico Optimization of Left Atrial Appendage Occluder Implantation Using Interactive and Modeling Tools.
Incidence and Clinical Impact of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion: A Meta-Analysis.
Left Atrial Appendage Occlusion With Left Ventricular Assist Device Decreases Thromboembolic Events.
Left Atrial Appendages Occlusion: Current Status and Prospective.
Outcomes of Routine Intracardiac Echocardiography to Guide Left Atrial Appendage Occlusion.
Prevalence, Mechanisms and Impact of Residual Patency and Device-Related Thrombosis Following Left Atrial Appendage Occlusion: a Computed Tomography Analysis.
Thrombus Formation After Left Atrial Appendage Occlusion With the Amplatzer Amulet Device.
Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy.
[Oral anticoagulation and platelet inhibition after atrial appendage occlusion].
Uterine Cervical Neoplasms
ACTX-8, a cytotoxic L-amino acid oxidase isolated from Agkistrodon acutus snake venom, induces apoptosis in Hela cervical cancer cells.
Vascular Diseases
Impact of Oral Anticoagulation Therapy Versus Left Atrial Appendage Occlusion on Cognitive Function and Quality of Life in Patients With Atrial Fibrillation.
Virus Diseases
What role for AHR activation in IL4I1-mediated immunosuppression ?